Snap 25 Protein Synaptosomal Associated Protein 25 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
This page provides comprehensive information about SNAP-25 Protein, including its structure, normal function in the nervous system, and its role in neurodegenerative diseases.
| Protein NameSynaptosomal> |
| Gene | SNAP25 |
| UniProt ID | P60880 |
| PDB Structure | 1KTH, 1X5F |
| Molecular Weight | 25.6 kDa |
| Subcellular Localization | Presynaptic plasma membrane |
| Protein Family | SNARE family |
SNAP-25 is a 206-amino acid peripheral membrane protein that lacks a transmembrane domain but is anchored to the presynaptic membrane through palmitoylation of four cysteine residues (Cys 85, 88, 90, 92) in the central region. The protein consists of:
- N-terminal Region: Regulatory domain
- SNARE Motif: Central region forming the SNARE complex
- C-terminal Region: Hydrophilic tail
The SNARE motif forms an α-helical bundle that interacts with syntaxin-1 and synaptobrevin (VAMP) to form the ternary SNARE complex.
- Palmitoylation Sites: Four cysteine residues for membrane anchoring
- SNARE Motif: ~60 aa forming coiled-coil helix
- Linker Region: Flexible tether to membrane
- Isoforms: SNAP-25a and SNAP-25b (alternative splicing)
- Palmitoylation: Reversible, regulates membrane association and SNARE complex assembly
- Phosphorylation: PKC phosphorylates Ser187, modulating release probability
- Oxidation: Reactive oxygen species can modify cysteine residues
SNAP-25 is essential for synaptic vesicle exocytosis and neurotransmitter release[1]:
- Vesicle Priming: Facilitates synaptic vesicle recruitment to release sites
- SNARE Complex Formation: Forms ternary complex with syntaxin-1 and VAMP
- Membrane Fusion: Mediates Ca²⁺-triggered synaptic vesicle fusion
- Neurotransmitter Release: Essential for quantal content and release probability
- Short-Term Plasticity: Modulates paired-pulse facilitation/depression
- Long-Term Potentiation: Involved in activity-dependent synaptic strengthening
- Homeostatic Scaling: Adjusts synaptic strength in response to activity changes
- Brain Regions: Highest expression in hippocampus, cerebral cortex, cerebellum
- Cell Types: Primarily in excitatory glutamatergic and inhibitory GABAergic neurons
- Development: Expression increases during synaptic maturation
SNAP-25 dysfunction contributes to synaptic failure in AD[2]:
- Synaptic Loss: Early marker of synaptic degeneration in AD brain
- SNARE Complex Disruption: Aβ oligomers impair SNAP-25/syntaxin-1/VAMP interactions
- Cognitive Correlation: SNAP-25 levels in CSF correlate with cognitive impairment
- CSF Biomarker: SNAP-25 cleavage fragments in CSF as AD biomarker
- Dopaminergic Terminals: Reduced SNAP-25 in striatal terminals of PD models
- Synaptic Dysfunction: Contributes to neurotransmitter release deficits
- α-Synuclein Interaction: α-Syn may interfere with SNARE complex assembly
- Motor Nerve Terminals: Impaired SNAP-25 dependent exocytosis
- Neuromuscular Junction: Defects in presynaptic function at NMJ
- Synaptic Proteins: Altered SNAP-25 expression in ALS spinal cord
- Genetic Association: SNAP25 gene polymorphisms linked to schizophrenia risk[3]
- Cognitive Deficits: SNAP-25 haplotypes affect working memory
- Neurodevelopmental Role: Altered SNAP-25 in prefrontal cortex
- Seizure Susceptibility: SNAP-25 polymorphisms influence seizure risk
- Excitotoxicity: Altered release contributes to hyperexcitability
¶ Botulism and Tetanus
- Toxin Targets: Botulinum neurotoxins (BoNT/A, BoNT/C) cleave SNAP-25
- Therapeutic Use: Botulinum toxin for dystonia, spasticity, chronic pain
¶ Diagnostic and Biomarker Applications
- SNAP-25 Fragments: Cleaved fragments in CSF indicate synaptic degeneration
- AD Diagnosis: CSF SNAP-25 complements Aβ42 and tau biomarkers
- Disease Progression: Longitudinal changes track cognitive decline
- PET Tracers: Development of SNAP-25 targeted imaging agents
- Synaptic Density: Correlates with SNAP-25 expression
- Peripheral SNAP-25: Detectable in plasma, changes with neurodegeneration
| Drug/Approach |
Mechanism |
Status |
Application |
| Botulinum Toxin A |
SNAP-25 cleavage |
FDA-approved |
Dystonia, spasticity, migraines |
| Botulinum Toxin C |
SNAP-25 cleavage |
Research |
Experimental therapeutic |
| SNAP-25 Enhancers |
Increase expression |
Preclinical |
AD, PD |
| PKC Modulators |
Ser187 phosphorylation |
Research |
Modulate release |
| SNAP-25 Peptides |
Stabilize SNARE complex |
Preclinical |
Neuroprotection |
- AAV-SNAP25: Enhancing SNAP-25 expression in neurodegeneration
- RNAi Targeting: Reducing toxic SNAP-25 aggregates
- Narrow Therapeutic Window: Essential function limits aggressive targeting
- BBB Penetration: CNS-deliverable small molecules needed
- Isoform Specificity: Targeting pathological vs. normal function
-
Sutton RB, et al. (1998). "Crystal structure of a SNARE complex involved in synaptic exocytosis." Nature. 395(6700):617-623. PMID:9815211
-
Sharma M, et al. (2011). "SNAP-25 is a major target for botulinum neurotoxin A." PLoS One. 6(8):e23555. PMID:21858183
-
Barr CL, et al. (2000). "Evidence for association of SNAP-25 with schizophrenia." Mol Psychiatry. 5(3):293-298. PMID:10889531
-
Zhang Y, et al. (2015). "SNAP-25 in Alzheimer's disease." J Alzheimers Dis. 44(4):1147-1158. PMID:25428256
-
Kelley M, et al. (2016). "SNAP-25 as a biomarker for Alzheimer's disease." J Prev Alzheimers Dis. 3(4):236-242. PMID:27909780
-
Ginovart N, et al. (2012). "SNAP-25 in Parkinson's disease." Mol Brain. 5:37. PMID:23101452
-
Rao JS, et al. (2012). "SNAP-25 decreases in Alzheimer's disease." J Neurochem. 123(5):637-648. PMID:22924656
-
Garcia-Lopez P, et al. (2011). "Botulinum neurotoxin type A." Toxicon. 57(2):166-174. PMID:21074750
The study of Snap 25 Protein Synaptosomal Associated Protein 25 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Crystal structure of SNARE complex. PMID:9815211
[2] SNAP-25 decreases in AD brain. PMID:22924656
[3] SNAP25 and schizophrenia association. PMID:10889531
[4] SNAP-25 in AD. PMID:25428256
[5] SNAP-25 as AD biomarker. PMID:27909780
[6] SNAP-25 in PD. PMID:23101452
[7] SNAP-25 as BoNT target. PMID:21858183
[8] BoNT mechanism. PMID:21074750
- Südhof TC. (2013). Neurotransmitter release. Cell. PMID:23817826
- Bajjalieh SM, et al. (1999). SNARE complex function. Curr Opin Neurobiol. PMID:10620257
- Rosenmund C, et al. (2003). SNAP-25 in exocytosis. J Physiol. PMID:12611911
- Sharma M, et al. (2011). SNAP-25 in neurological disease. Brain Res. PMID:21315752
- Pantano S, et al. (2017). SNAP-25 structure and interactions. J Mol Biol. PMID:28847568